Compare Charles River Laboratories Intl. Inc (CRL) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while JPMorgan Ultra Short Income ETF trades at $50.5. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| CRL | JPST | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $233.60 | $50.78 |
52-Week Low | $145.57 | $50.40 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
JPST trades at $50.44, down 0.02% with a bearish technical signal from moving averages. The ETF focuses on high-quality, short-term bonds, offering monthly dividends and capital preservation. Recent news highlights strong institutional inflows and its role as a cash alternative in volatile markets. Technical indicators show neutral oscillators but overall bearish momentum, with support and resistance clustered around $50.
Outlook remains stable for income-focused investors seeking low duration risk, though rising Treasury yields pose a headwind. Key risks include interest rate sensitivity and credit spread changes. Institutional ownership trends indicate growing advisor interest, supporting its defensive profile in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
